Literature DB >> 22425049

Comparison of intraprostatic ethanol diffusion using a microporous hollow fiber catheter versus a standard needle.

Benjamin J King1, Mark K Plante, Masatoshi Kida, Travis K Mann-Gow, Rick Odland, Peter Zvara.   

Abstract

PURPOSE: Transurethral intraprostatic ethanol chemoablation of the prostate has shown promising preliminary clinical results for benign prostatic hyperplasia with some variability in clinical outcome. This is likely due to the uneven prostate diffusion caused by varying resistance of the tissue type in which the tip of the needle is embedded. We examined whether the distribution of the injectable in the canine prostate could be improved using a microporous hollow fiber catheter (Twin Star Medical, Minneapolis, Minnesota).
MATERIALS AND METHODS: The prostate was exposed in 9 mongrel dogs. A single injection of 98% ethanol was delivered in each lobe using a microporous hollow fiber catheter and a standard needle. Prostates were harvested and fixed in 10% formalin. After injection 2.5 mm step sections were obtained and scanned. The ethanol induced tissue lesions were traced on hematoxylin and eosin sections. Three-dimensional reconstructions were created and the volume of each prostate lesion was calculated using stereology.
RESULTS: Ethanol induced tissue changes were seen bilaterally in 8 of 9 ethanol injected prostates. In all cases the lesion created by microporous hollow fiber catheter injection was larger than that in the contralateral lobe injected with the control needle. When data were pooled, the hollow fiber catheter injection produced significantly greater tissue changes than the control needle injection (p = 0.03).
CONCLUSIONS: Improved distribution and absent backflow were seen when using the microporous hollow fiber catheter, supporting its potential as a new method to treat prostate disease.
Copyright © 2012 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22425049      PMCID: PMC3730440          DOI: 10.1016/j.juro.2011.12.057

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  18 in total

1.  Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging.

Authors:  D W Laske; P F Morrison; D M Lieberman; M E Corthesy; J C Reynolds; P A Stewart-Henney; S S Koong; A Cummins; C H Paik; E H Oldfield
Journal:  J Neurosurg       Date:  1997-10       Impact factor: 5.115

2.  Intraprostatic chemotherapy: distribution and transport mechanisms.

Authors:  M Guillaume Wientjes; Jenny H Zheng; Leijun Hu; Yuebo Gan; Jessie L-S Au
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

3.  Diffusion properties of transurethral intraprostatic injection.

Authors:  Mark K Plante; Andrew L Gross; Jeffrey B Folsom; Peter Zvara
Journal:  BJU Int       Date:  2004-12       Impact factor: 5.588

4.  Percutaneous ablation of canine prostate using transrectal ultrasound guidance. Absolute ethanol and Nd:YAG laser.

Authors:  P J Littrup; F Lee; G S Borlaza; E J Sacknoff; S Torp-Pedersen; J M Gray
Journal:  Invest Radiol       Date:  1988-10       Impact factor: 6.016

5.  Convection-enhanced delivery of macromolecules in the brain.

Authors:  R H Bobo; D W Laske; A Akbasak; P F Morrison; R L Dedrick; E H Oldfield
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

6.  Ablation of canine prostate using transurethral intraprostatic absolute ethanol injection.

Authors:  P Zvara; E Karpman; R Stoppacher; A C Esenler; M K Plante
Journal:  Urology       Date:  1999-09       Impact factor: 2.649

7.  Feasibility of adenovirus-mediated hNIS gene transfer and 131I radioiodine therapy as a definitive treatment for localized prostate cancer.

Authors:  Kenneth N Barton; Hans Stricker; Mohamed A Elshaikh; Jan Pegg; Jingfang Cheng; Yingshu Zhang; Kastytis C Karvelis; Mei Lu; Benjamin Movsas; Svend O Freytag
Journal:  Mol Ther       Date:  2011-05-17       Impact factor: 11.454

8.  Intraprostatic ethanol chemoablation via transurethral and transperineal injection.

Authors:  M K Plante; A L Gross; J Kliment; M Kida; P Zvara
Journal:  BJU Int       Date:  2003-01       Impact factor: 5.588

9.  Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): a European multi-center evaluation.

Authors:  P Grise; M Plante; J Palmer; J Martinez-Sagarra; C Hernandez; M Schettini; M Gonzalez-Martin; J Castiñeiras; P Ballanger; P Teillac; F Rolo; V Baena; J Erdmann; V Mirone
Journal:  Eur Urol       Date:  2004-10       Impact factor: 20.096

10.  Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion.

Authors:  D M Lieberman; D W Laske; P F Morrison; K S Bankiewicz; E H Oldfield
Journal:  J Neurosurg       Date:  1995-06       Impact factor: 5.115

View more
  3 in total

1.  Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.

Authors:  Andrew R Tsen; Patrick M Long; Heather E Driscoll; Matthew T Davies; Benjamin A Teasdale; Paul L Penar; William W Pendlebury; Jeffrey L Spees; Sean E Lawler; Mariano S Viapiano; Diane M Jaworski
Journal:  Int J Cancer       Date:  2013-09-30       Impact factor: 7.396

2.  Intraprostatic ethanol diffusion: comparison of two injection methods using ex vivo human prostates.

Authors:  B J King; T K Mann-Gow; M Kida; M K Plante; S D Perrapato; P Zvara
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-05-26       Impact factor: 5.554

3.  A pilot study in intraparenchymal therapy delivery in the prostate: a comparison of delivery with a porous needle vs standard needle.

Authors:  Martin L Brady; King Scott Coffield; Thomas J Kuehl; Raghu Raghavan; V O Speights; Belur Patel; Scott Wilson; Mike Wilson; Rick M Odland
Journal:  BMC Urol       Date:  2018-07-28       Impact factor: 2.264

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.